International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengaß, Suzanne Lentzsch, Jesús G. Berdeja et al.|The Lancet Oncology|2019Cited by 493
GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Eric L. Smith, Sean M. Devlin et al.|New England Journal of Medicine|2022Cited by 383
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapyOliver Van Oekelen, Samir Parekh, Karthik Nath et al.|Blood|2022Cited by 103
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignanciesRobert Stuver, Santosha A. Vardhana, Gunjan L. Shah et al.|Cancer Cell|2022Cited by 88
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1Saad Z. Usmani, Zihai Li|Journal of Hematology & Oncology|2010Cited by 54